$50.24
1.06% day before yesterday
Nasdaq, Apr 25, 10:00 pm CET
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Bio-Techne Corporation Target price 2025 - Analyst rating & recommendation

Bio-Techne Corporation Classifications & Recommendation:

Buy
67%
Hold
33%

Bio-Techne Corporation Price Target

Target Price $79.45
Price $50.24
Potential
Number of Estimates 11
11 Analysts have issued a price target Bio-Techne Corporation 2026 . The average Bio-Techne Corporation target price is $79.45. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 12 Analysts recommend Bio-Techne Corporation to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Bio-Techne Corporation stock has an average upside potential 2026 of . Most analysts recommend the Bio-Techne Corporation stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Jun '24 2025
Estimates
Revenue Billion $ 1.16 1.23
1.97% 5.91%
EBITDA Margin 31.47% 34.51%
7.79% 9.66%
Net Margin 14.31% 14.15%
41.49% 1.09%

13 Analysts have issued a sales forecast Bio-Techne Corporation 2025 . The average Bio-Techne Corporation sales estimate is

$1.2b
Unlock
. This is
2.64% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.2b 3.46%
Unlock
, the lowest is
$1.2b 1.82%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $1.2b 1.97%
2025
$1.2b 5.91%
Unlock
2026
$1.3b 8.28%
Unlock
2027
$1.5b 11.10%
Unlock
2028
$1.7b 18.42%
Unlock

11 Analysts have issued an Bio-Techne Corporation EBITDA forecast 2025. The average Bio-Techne Corporation EBITDA estimate is

$424m
Unlock
. This is
15.48% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$431m 17.58%
Unlock
, the lowest is
$412m 12.29%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $365m 5.98%
2025
$424m 16.13%
Unlock
2026
$481m 13.59%
Unlock
2027
$534m 10.93%
Unlock
2028
$682m 27.79%
Unlock

EBITDA Margin

2024 31.47% 7.79%
2025
34.51% 9.66%
Unlock
2026
36.20% 4.90%
Unlock
2027
36.14% 0.17%
Unlock
2028
39.00% 7.91%
Unlock

5 Bio-Techne Corporation Analysts have issued a net profit forecast 2025. The average Bio-Techne Corporation net profit estimate is

$174m
Unlock
. This is
12.24% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$182m 17.35%
Unlock
, the lowest is
$161m 4.08%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $166m 40.34%
2025
$174m 4.76%
Unlock
2026
$232m 33.41%
Unlock
2027
$326m 40.56%
Unlock
2028
$347m 6.65%
Unlock

Net Margin

2024 14.31% 41.49%
2025
14.15% 1.09%
Unlock
2026
17.43% 23.18%
Unlock
2027
22.06% 26.56%
Unlock
2028
19.87% 9.93%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Jun '24 2025
Estimates
Earnings Per Share $ 1.05 1.10
40.34% 4.76%
P/E 45.67
EV/Sales 6.65

5 Analysts have issued a Bio-Techne Corporation forecast for earnings per share. The average Bio-Techne Corporation EPS is

$1.10
Unlock
. This is
12.24% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$1.15 17.35%
Unlock
, the lowest is
$1.02 4.08%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $1.05 40.34%
2025
$1.10 4.76%
Unlock
2026
$1.47 33.64%
Unlock
2027
$2.06 40.14%
Unlock
2028
$2.20 6.80%
Unlock

P/E ratio

Current 51.06 14.00%
2025
45.67 10.56%
Unlock
2026
34.24 25.03%
Unlock
2027
24.36 28.86%
Unlock
2028
22.84 6.24%
Unlock

Based on analysts' sales estimates for 2025, the Bio-Techne Corporation stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.82 23.37%
2025
6.65 2.54%
Unlock
2026
6.14 7.65%
Unlock
2027
5.53 9.99%
Unlock
2028
4.67 15.55%
Unlock

P/S ratio

Current 6.64 22.13%
2025
6.47 2.57%
Unlock
2026
5.98 7.64%
Unlock
2027
5.38 10.00%
Unlock
2028
4.54 15.55%
Unlock

Current Bio-Techne Corporation Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Keybanc
Locked
Locked
Locked Apr 09 2025
Keybanc
Locked
Locked
Locked Apr 08 2025
Evercore ISI Group
Locked
Locked
Locked Mar 18 2025
Citigroup
Locked
Locked
Locked Mar 04 2025
Baird
Locked
Locked
Locked Feb 19 2025
Keybanc
Locked
Locked
Locked Feb 06 2025
RBC Capital
Locked
Locked
Locked Feb 06 2025
Analyst Rating Date
Locked
Keybanc:
Locked
Locked
Apr 09 2025
Locked
Keybanc:
Locked
Locked
Apr 08 2025
Locked
Evercore ISI Group:
Locked
Locked
Mar 18 2025
Locked
Citigroup:
Locked
Locked
Mar 04 2025
Locked
Baird:
Locked
Locked
Feb 19 2025
Locked
Keybanc:
Locked
Locked
Feb 06 2025
Locked
RBC Capital:
Locked
Locked
Feb 06 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today